Zhejiang Kangde Pharmaceutical Group Co. Ltd.

To evaluate the safety and effectiveness of Danlong Oral Liquid in treating bronchial asthma (heat asthma syndrome) under widely used conditions; To evaluate the types and incidence of adverse reactions; To analyze the characteristics of Danlong Oral Liquid in treating bronchial asthma (heat asthma syndrome); To provide data support for guiding rational clinical drug use and completing re-registration.

The main purpose of the study is to study the pharmacokinetics of the test preparation ezetimibe atorvastatin calcium tablets (specification: 10mg/20mg, produced by Zhejiang Kangde Pharmaceutical Group Co., Ltd.) and the reference preparation ezetimibe atorvastatin calcium tablets (Atozet ®, specification: 10mg/20mg, produced by Merck Sharp & Dohme B.V.) in healthy adult subjects in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary purpose of the study is to evaluate the safety of the test preparation and reference preparation of ezetimibe atorvastatin calcium tablets in healthy subjects in the fasting and fed state.

Gliclazide sustained-release tablets (specification: 30 mg) developed by Zhejiang Kangde Pharmaceutical Group Co., Ltd. were used as the test preparation, and Gliclazide sustained-release tablets (trade name: Diamecon®, specification: 30 mg) produced by Servier (Tianjin) Pharmaceutical Co., Ltd. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent, and the safety of the two preparations in healthy subjects was evaluated.